BMO Capital Upgrades Fate Therapeutics to Outperform, Lowers Price Target to $47
BMO Capital analyst Etzer Darout upgrades Fate Therapeutics (NASDAQ:FATE) from Market Perform to Outperform and lowers the price target from $50 to $47.
Stifel Upgrades Glaukos to Buy, Raises Price Target to $60
Stifel analyst Thomas Stephan upgrades Glaukos (NYSE:GKOS) from Hold to Buy and raises the price target from $40 to $60.
National Bank Of Canada Upgrades Andlauer Healthcare Group to Outperform
National Bank Of Canada analyst Endri Leno upgrades Andlauer Healthcare Group (TSX:AND) from Sector Perform to Outperform.
RBC Capital Upgrades DCP Midstream to Outperform, Raises Price Target to $40
RBC Capital analyst Elvira Scotto upgrades DCP Midstream (NYSE:DCP) from Sector Perform to Outperform and raises the price target from $37 to $40.
Keefe, Bruyette & Woods Upgrades Axos Financial to Outperform, Raises Price Target to $56
Keefe, Bruyette & Woods analyst Michael Perito upgrades Axos Financial (NYSE:AX) from Market Perform to Outperform and raises the price target from $52 to $56.
BMO Capital Upgrades Fate Therapeutics to Outperform, Announces $47 Price Target
BMO Capital analyst Etzer Darout upgrades Fate Therapeutics (NASDAQ:FATE) from Market Perform to Outperform and announces $47 price target.
Credit Suisse Upgrades Taylor Morrison Home to Outperform, Announces $33 Price Target
Credit Suisse analyst Daniel Oppenheim upgrades Taylor Morrison Home (NYSE:TMHC) from Neutral to Outperform and announces $33 price target.
Barclays Upgrades Element Solutions to Overweight, Lowers Price Target to $22
Barclays analyst Michael Leithead upgrades Element Solutions (NYSE:ESI) from Equal-Weight to Overweight and lowers the price target from $24 to $22.
B of A Securities Upgrades Flowserve to Neutral
B of A Securities analyst Andrew Obin upgrades Flowserve (NYSE:FLS) from Underperform to Neutral.